Emerging data suggests that retatrutide, a dual-action medication, might represent a significant advance in body loss . This drug combines the effects of a GLP-1 agonist and a GIP agonist , seemingly offering a enhanced benefit than existing approaches . Patient trials have revealed encouraging outcomes, including substantial declines in size and